Particularly, antileukemic activity of pyrvinium was observed in pediatric MLL-rearranged AML, B-cell acute lymphoblastic leukemia (ALL), and T-ALL with NOTCH inactivation signature [58–60]. This evidence concerns the gene KMT2A and acute myeloid leukemia.